Published in Cancer Res on May 01, 2001
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med (2015) 2.55
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res (2011) 2.25
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One (2009) 1.68
High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia (2004) 1.66
Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. EMBO J (2002) 1.65
Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 1.65
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res (2011) 1.58
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer (2013) 1.57
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol (2002) 1.55
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
Inorganic arsenic and human prostate cancer. Environ Health Perspect (2008) 1.47
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One (2015) 1.41
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer (2016) 1.39
NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol (2009) 1.35
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res (2009) 1.34
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem (2008) 1.32
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 1.32
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res (2010) 1.29
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One (2013) 1.29
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One (2011) 1.25
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol (2008) 1.21
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci U S A (2009) 1.17
Advancing precision medicine for prostate cancer through genomics. J Clin Oncol (2013) 1.16
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol (2006) 1.12
Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene (2005) 1.12
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One (2010) 1.10
Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol (2006) 1.10
Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci (2011) 1.10
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol Cancer (2010) 1.08
Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer (2004) 1.07
The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res (2012) 1.07
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells. Br J Cancer (2007) 1.06
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol (2011) 1.05
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res (2009) 1.04
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci (2011) 1.03
Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res (2009) 1.02
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol (2011) 1.01
Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors. Horm Cancer (2010) 1.01
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol (2012) 1.01
Decoding the androgen receptor splice variants. Transl Androl Urol (2013) 1.01
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate (2010) 1.00
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. Am J Pathol (2003) 0.99
Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol (2010) 0.98
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther (2012) 0.97
Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility. BMC Genomics (2008) 0.97
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer (2010) 0.97
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer (2011) 0.96
The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells. Biochem Biophys Res Commun (2007) 0.96
ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem (2009) 0.96
Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer. Oncogene (2015) 0.95
The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J Biol Chem (2013) 0.95
NF-κB signaling in prostate cancer: a promising therapeutic target? World J Urol (2011) 0.95
Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol (2007) 0.95
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 0.95
Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ Health Perspect (2006) 0.94
Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription. EMBO J (2006) 0.94
A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab (2008) 0.94
Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Cancer Cell Int (2008) 0.93
ARF represses androgen receptor transactivation in prostate cancer. Mol Endocrinol (2013) 0.92
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
Androgen regulation of the androgen receptor coregulators. BMC Cancer (2008) 0.92
Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. Can Urol Assoc J (2015) 0.92
SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer. Mol Cancer Ther (2011) 0.92
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep (2015) 0.91
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther (2013) 0.91
The role of SRC-1 in murine prostate cancinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression. Int J Biol Sci (2009) 0.90
Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. ACS Chem Biol (2013) 0.90
Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis (2011) 0.90
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A (1997) 3.22
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 2.74
Screening for prostatic carcinoma with prostate specific antigen. J Urol (1992) 2.03
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res (1996) 1.98
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst (1992) 1.94
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem (2000) 1.91
The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol (1998) 1.86
Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer (1991) 1.85
Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene (2011) 1.78
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71
The expression of SOCS is altered in rheumatoid arthritis. Rheumatology (Oxford) (2007) 1.70
Placental alkaline phosphatase as a tumor marker for seminoma. Cancer Res (1982) 1.63
Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.59
Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res (2000) 1.52
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene (2011) 1.50
Osteoprotegerin and rank ligand expression in prostate cancer. Urology (2001) 1.50
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol (2000) 1.47
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem (2004) 1.42
Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene (2012) 1.40
Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry (1994) 1.39
Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev (1999) 1.30
Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol (1994) 1.26
Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol (1993) 1.26
ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res (2001) 1.26
Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol (2001) 1.25
Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res (1997) 1.23
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 1.23
Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis (2003) 1.22
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol (2000) 1.20
Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene (2006) 1.19
Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl (1996) 1.18
Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res (2003) 1.14
Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. Oncogene (2008) 1.13
The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth. Oncogene (2006) 1.13
A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course. Cancer (1979) 1.12
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet (1999) 1.12
Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol (1987) 1.11
Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res (1995) 1.11
Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet (2001) 1.10
Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate (1997) 1.10
Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol (1998) 1.10
Sexual and social life of men operated in childhood for hypospadias and phimosis. A comparative study. Eur Urol (2000) 1.09
Is the incidence of hypospadias increasing? Analysis of Finnish hospital discharge data 1970-1994. Environ Health Perspect (2000) 1.09
Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res (1988) 1.08
Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim (2001) 1.07
Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer (1995) 1.06
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06
Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet (1998) 1.05
Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2. Nucl Med Biol (1993) 1.05
Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology (1999) 1.04
Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology (2000) 1.03
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res (2001) 1.03
Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol (1993) 1.02
Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry (1991) 1.02
Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer (1996) 1.02
Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer (1994) 1.01
Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group. J Urol (1999) 1.01
Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer (1996) 1.01
PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol (1999) 1.00
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis (2005) 0.99
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol (1997) 0.98
A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis. J Immunol Methods (1997) 0.98
Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology (1997) 0.98
Priapism, its incidence and seasonal distribution in Finland. Scand J Urol Nephrol (1995) 0.98
Amplification of urokinase gene in prostate cancer. Cancer Res (2001) 0.97
Identification of novel transcription factor-like gene from human intestinal cells. Biochem Biophys Res Commun (2000) 0.96
Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer (1994) 0.95
Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer (1997) 0.95
Heterogeneity among human lymphocyte effector cells mediating spontaneous lymphocyte-mediated cytotoxicity. Int J Cancer (1978) 0.95
Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. Bioconjug Chem (1997) 0.95
Molecular cytogenetics of prostate cancer. Microsc Res Tech (2000) 0.94
Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. Int J Cancer (2001) 0.94
High prevalence of antibodies against HERV-K10 in patients with testicular cancer but not with AIDS. Cancer Epidemiol Biomarkers Prev (1999) 0.94
Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. Br J Urol (1998) 0.93
Association of non-urological diseases with lower urinary tract symptoms. Scand J Urol Nephrol (2001) 0.93
Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol (2000) 0.93
Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer (2000) 0.93
Molecular genetics of prostate cancer. Ann Med (2001) 0.93
Association of smoking with lower urinary tract symptoms. J Urol (1998) 0.93
Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol (1999) 0.93
Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol (1999) 0.93
Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology (1997) 0.92
Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res (1996) 0.92
Molecular biology of progression of prostate cancer. Eur Urol (1999) 0.91
Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res (1999) 0.91